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Abstract
Pivotal components of the IFN response to virus infection include the IFN receptors (IFNR), and the downstream factor
signal transducer and activator of transcription 1 (Stat1). Mice deficient for Stat1 and IFNR (Stat1
2/2 and IFNaßcR
2/2 mice)
lack responsiveness to IFN and exhibit high sensitivity to various pathogens. Here we examined herpes simplex virus type 1
(HSV-1) pathogenesis in Stat1
2/2 mice and in IFNaßcR
2/2 mice following corneal infection and bioluminescent imaging.
Two divergent and paradoxical patterns of infection were observed. Mice with an N-terminal deletion in Stat1 (129Stat1
2/2
(N-term)) had transient infection of the liver and spleen, but succumbed to encephalitis by day 10 post-infection. In stark
contrast, infection of IFNaßcR
2/2 mice was rapidly fatal, with associated viremia and fulminant infection of the liver and
spleen, with infected infiltrating cells being primarily of the monocyte/macrophage lineage. To resolve the surprising
difference between Stat1
2/2 and IFNaßcR
2/2 mice, we infected an additional Stat1
2/2 strain deleted in the DNA-binding
domain (129Stat1
2/2 (DBD)). These 129Stat1
2/2 (DBD) mice recapitulated the lethal pattern of liver and spleen infection
seen following infection of IFNaßcR
2/2 mice. This lethal pattern was also observed when 129Stat1
2/2 (N-term) mice were
infected and treated with a Type I IFN-blocking antibody, and immune cells derived from 129Stat1
2/2 (N-term) mice were
shown to be responsive to Type I IFN. These data therefore show significant differences in viral pathogenesis between two
commonly-used Stat1
2/2 mouse strains. The data are consistent with the hypothesis that Stat1
2/2 (N-term) mice have
residual Type I IFN receptor-dependent IFN responses. Complete loss of IFN signaling pathways allows viremia and rapid
viral spread with a fatal infection of the liver. This study underscores the importance of careful comparisons between
knockout mouse strains in viral pathogenesis, and may also be relevant to the causation of HSV hepatitis in humans, a rare
but frequently fatal infection.
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Introduction
Herpes simplex virus type (HSV) is a ubiquitous human
pathogen capable of causing significant morbidity in immuno-
competent patients. Primary and recurrent infections most often
cause orofacial lesions, genital lesions, or in the case of ocular
infection, herpetic stromal keratitis. Disease in immunocompetent
individuals, however, is usually self-limiting. Patterns of disease in
immune-compromised patients are often more severe, and in
particular, neonates may suffer disseminated infections following
HSV infection, with involvement of the skin, eye, mouth, central
nervous system, liver, lung, and adrenal glands [1]. This
widespread infection is attributed to the immature T-cell and
IFN responses in neonates as compared to adults [2,3]. Consistent
with this, adults with impaired IFN Type I and Type II responses,
due to either a deficiency in the signal transduction and
transcription factor 1 (Stat1), Toll-like receptor 3 (TLR3), or
UNC-93B (an endoplasmic reticulum protein important for TLR
signaling), show increased susceptibility to HSV and other viral
infections [4,5,6,7]. In addition, immune-suppressed and immune-
compromised patients show increased susceptibility to HSV
hepatitis and can develop acute liver failure [8,9,10].
Stat proteins are transcription factors that regulate immune and
growth processes [11]. In particular, Stat1 is a critical component
in both Type I and Type II IFN receptor signaling. IFN binding to
its cognate receptor activates kinases that phosphorylate Stat1.
Following Type I IFN receptor signaling with IFNa/ß, a
heterotrimeric complex consisting of pStat1/pStat2/ISGF3 as-
sembles and translocates to the nucleus, wherein it mediates the
expression of genes containing IFN-stimulated response elements
(ISREs). In Type II IFN signaling (IFNc), pStat1 forms
homodimers that mediate expression from genes containing
gamma-activated sequence (GAS) motifs. Genes downstream of
the ISRE and GAS elements are crucial to controlling viral
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cells lacking these components have helped define these pathways.
Two mouse lines have been constructed whose Stat1 gene is
lacking either the N-terminal domain (termed here Stat1
2/2
(N-term)) [12] or the DNA binding domain (termed here Stat1
2/2
(DBD)) [13]. IFNR
2/2 mice lacking Type I and/or Type II IFNR
have been used to examine the separate and combined
contributions of these receptors [14,15,16]. Herein, we use both
Stat1
2/2 and IFNRaßcR
2/2 mice to study how each component
in the IFN signaling pathway contributes to the control of HSV
infection.
HSV-1 has several countermeasures to the IFN response,
including the viral proteins ICP34.5, US11, ICP0, and vhs [17]. In
general HSV is resistant to the effects of IFN, but recombinant
viruses lacking any of these proteins show varying degrees of
increased sensitivity to host IFN. This study focuses on two mouse
strains in the 129 background, 129Stat1
2/2(N-term) [12] and
IFNaßcR
2/2 (also termed AG129) [15,16] mice, both of which
have been demonstrated to have increased susceptibility to various
pathogens, including Listeria monocytogenes, vesicular stomatitis
virus, dengue virus, Sindbis virus, mouse norovirus, and mouse
cytomegalovirus [12,18,19,20,21,22,23]. The susceptibility pat-
terns, however, vary between these mice, and between pathogens.
Stat1
2/2 and IFNaßcR
2/2 mice both show increased suscepti-
bility to HSV infection and differences in HSV pathogenesis
[24,25,26,27,28,29,30]. Such differences have previously been
ascribed to either Stat1 independent signaling of IFNs, [23] or to
other non IFN-related effects of deletion of Stat1 [29]. Recent
studies have also demonstrated that Stat2 is a major mediator of
Stat1-independent host defense to dengue virus [31].
The goal of the present study was to examine further the
respective roles of Stat1 and IFN receptors in the control of HSV-1
infection. In addition, we wished to compare two different Stat1
2/2
mice, namely the mice constructed by Meraz et al. (referred to
herein as 129Stat1
2/2(N-term)) [12], and those made by Durbin
et al. (referred to herein as B6Stat1
2/2(DBD) and 129Stat1
2/2
(DBD))[13,32]. HSV-1 displayed markedly divergent pathogenesis
in 129Stat1
2/2(N-term) and AG129 mice. Strain 129Stat1
2/2
(N-term) mice cleared a disseminated visceral infection, yet
succumbed with high levels of central nervous system (CNS)
infection. In contrast, infectionof the IFNaßcR
2/2 mice resulted in
a frank viremia that started in the draining lymph nodes and which
progressed to a rapidly fatal infection that coincided with an
overwhelming infection of the liver and spleen. Furthermore, the
ability of the 129Stat1
2/2(N-term) mice to control the visceral
infection was dependent on signaling via the Type I IFN receptor.
These results highlight a clear role for the IFN receptors in
controlling the extent and tropism of viral replication. Furthermore,
the data show that the two Stat1 knockout mouse strains tested are
significantly different in their susceptibility to HSV-1, with the mice
lacking the N-terminus of Stat1 [12] being significantly more
resistant to HSV-1 infection than those lacking the DNA-binding
domain [13,32]. These data demonstrate these two mouse strains
cannot be considered interchangeable for virus infection and
pathogenesis, and data derived from each of these strains should be
compared and interpreted with caution.
Results
HSV lethality and disease in control, 129Stat1
2/2(N-term),
and AG129 mice
In separate studies, strain 129Stat1
2/2(N-term) and AG129
mice have exhibited a high degree of susceptibility to corneal
inoculation of HSV-1 [25,26]. As previously reported, all infected
control mice survived HSV-1 infection with minimal, if any,
ocular disease (Fig. 1 and data not shown). Strain 129Stat1
2/2
(N-term) mice died between 7 and 10 dpi with substantial external
disease, behavioral signs of CNS infection, and weight loss (Fig. 1,
data not shown and [26]). In contrast, HSV-1 virus-infected
AG129 mice showed mild ocular disease up to 3 dpi, but this was
followed by weight loss, development of a quiet demeanor with
little movement or response to stimulation, and remarkably
synchronous death on 5 dpi without apparent external disease.
Similar timelines were reported for this model system by Halford
et al. [30]. These results highlight two important aspects of these
infection models. First, as observed for other pathogens 129
Stat1
2/2(N-term) and AG129 mice are not equivalent in their
ability to control an HSV-1 infection [12,18,19,20,21,23,30,33].
Second, and not previously studied, clinical signs prior to death,
and timing of death differed substantially between the two IFN
response-deficient mouse models, prompting us to examine viral
spread and to look more closely at the patterns of pathogenesis and
lethality.
Shift in tissue tropism visualized by in vivo
bioluminescence imaging
Our results indicated the possibility that distinct mechanisms or
tropisms were driving the disease and lethality in the virus-infected
129Stat1
2/2(N-term) and AG129 mice. HSV-1 is considered a
neurotropic virus, yet previous studies with AG129 mice revealed
a disseminated infection that involved visceral organs [25,30].
Dissemination of a related herpesvirus, pseudorabies virus, had
also been shown in AG129 mice following intraperitoneal infection
[34]. We used bioluminescent imaging to examine HSV-1 spread
and tropism in 129Stat1
2/2(N-term) mice using a luciferase
reporter virus KOS/Dlux/OriL [35] (Fig. 2). Luciferase signal
from the ocular region was present in all mice in accordance with
previous reports of viral replication in the cornea [24,27](data not
shown).
While the control mice showed minimal luciferase activity,
129Stat1
2/2(N-term) mice showed transient luciferase activity by 2
dpi in the draining cervical lymph nodes, and by 3 dpi in the liver
Figure 1. Survival of mice lacking intact IFN signaling. Kaplan-
Meier survival plot of mice infected via the cornea with 2610
6 pfu/eye
of HSV-1 KOS in control (gray line), 129Stat1
2/2(N-term) (solid black
line), or AG129 (dashed black line). The plot represents at least 20 mice
per model, derived from at least 3 independent experiments.
doi:10.1371/journal.pone.0024018.g001
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the KOS/Dlux/OriL virus exhibited a disseminated infection [25].
Unlike the 129Stat1
2/2(N-term) mice, the AG129 mice did not
clear the infection of the draining cervical lymph nodes, liver, or
spleen. These organs showed high levels of luciferase activity that
were sustained until the death of the animal on 5 dpi.
When the 129Stat1
2/2(N-term) tissues were examined by
bioluminescent imaging ex vivo, a transient signal was localized to
the liver and spleen on 3 dpi, and signals were evident in the
trigeminal ganglia and brain stem on 3 and 6 dpi (Fig. S1). Positive
signals were also found in the brain, brain stem, trigeminal
ganglia, liver, and spleen of infected AG129 mouse tissues at 3 dpi
(Fig. S1). In addition, luciferase signal was low or undetectable in
intestines, stomach, and surrounding gut tissues (data not shown).
Two regions, the neck and the abdomen, were identified during in
vivo imaging and selected for quantification of the bioluminescent
signal. The signal in the neck was determined by ex vivo imaging to
be largely from the draining lymph nodes. The abdominal signal
was derived from a combination of activity in the liver and spleen.
In both regions of interest (ROI) analyses, the luciferase signal was
markedly higher in the AG129 mice than in the control or
129Stat1
2/2(N-term) mice (Fig. S2). Not unexpectedly, the lack of
Stat1 or IFN receptors had a marked effect on control of
disseminated infection. However, these results were notable for the
differences seen between the ability of the deficient mice to control
the disseminated, visceral infection. The bioluminescent imaging
also supported our finding in the lethality analysis, that viral
pathogenesis differs markedly in strain 129Stat1
2/2(N-term) and
AG129 mice.
129Stat1
2/2(N-term) mice control hematogenous
infection, but succumb to CNS infection
To expand and confirm both previous studies and the
bioluminescent imaging results, viral titers were measured in serum,
draining lymph nodes, liver, spleen, and CNS tissues [24,27]. In
control mice, low titers of virus were found in the lymph nodes at 3
and 5 dpi (Fig. 3B), while virus was undetectable in the liver, spleen,
and serum (Fig. 3A, C and D). The data showed a transient visceral
Figure 2. Pattern of viral spread in control, 129Stat1
2/2(N-term), and AG129 mice assessed by bioluminescent imaging. In vivo
bioluminescent imaging analysis was performed at 2, 3, and 4 dpi following corneal inoculation of 2610
6 pfu/eye of HSV-1 KOS/Dlux/OriL. Images are
representative of 4 independent experiments. Daily images from the same mice per strain formatted on an identical photon flux scale are shown. For
clarity additional images in the right hand column are shown for 4 dpi on a higher photon flux scale to avoid the saturated image for the AG129 mice.
doi:10.1371/journal.pone.0024018.g002
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2/2(N-term) mice that peaked at 3 dpi in the
lymph nodes, liver, spleen, and serum, correlative with the
bioluminescent imaging data. In contrast, the AG129 mice showed
detectable viral replicationin the lymph nodes as early as 1 dpi(data
not shown), and viral titers in the liver, spleen, and serum increased
dramatically in the five days following infection, with no evidence of
control or clearance (Fig. 3A, C and D).
Viral titer analyses of CNS tissues revealed an interesting
different pattern of infection (Fig. 3). Control mice cleared the
virus from the CNS by 7 dpi. In contrast to visceral tissues,
129Stat1
2/2(N-term) mice could not clear virus from their CNS
(Fig. 3 and [26]. Instead, viral replication increased in the brain
and brain stem out to day 5, and then maintained a constant level
out to time of death, consistent with the ex vivo bioluminescent
imaging analysis (Fig. S1). Additionally, these mice showed
consistently increased blood-brain barrier permeability by Evans
blue dye uptake, consistent with CNS inflammation and damage
(data not shown). CNS titers from the tissues of infected AG129
also showed increasing viral titers over time and a lack of viral
clearance, although there were no changes in blood-brain barrier
permeability on day 4, just prior to death (data not shown). These
results indicated that the efficacy of the IFN-dependent antiviral
response differed between the visceral and CNS tissues.
Analysis of infected cells in lymphoid organs of AG129
mice
When AG129 mice wereinfected via the cornea with KOS64gfp,
.5% of their splenocytes were gfp-positive by flow cytometry at 4
days postinfection (compare Fig. 4A to 4B). In contrast, gfp-positive
splenocytes were undetectable by flow cytometry in control and
129Stat1
2/2(DBD) mice (data not shown). Titering of serum and of
Figure 3. Pattern of viral spread in control, 129Stat1
2/2(N-term), and AG129 mice assessed by viral titer in relevant tissues. Control,
129Stat1
2/2(N-term), and AG129 infected via the cornea with 2610
6 pfu/eye of HSV-1 KOS were sacrificed at 3, 5, or 7 dpi for a viral titer analysis of
tissues identified in the bioluminescent imaging. Each bar represents the tissue titer of at least 8 tissues from a minimum of 3 independent
experiments. Titers are reported as pfu/ml (serum) or pfu/tissue (lymph nodes, liver, spleen, brain stem and and brain. The dashed line indicates limit
of detection. ND=Not detected. NA=mouse not available.
doi:10.1371/journal.pone.0024018.g003
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high levels of virus in the serum of infected mice (Fig. 3A), and that
there was 5- to 10-fold more virus in the cell-free fraction of infected
spleens than in the cell-associated fraction (data not shown). The
gfp-positive splenocytes from the AG129 mice were subsequently
analyzed by flow cytometry to identify the infected cellular
populations. CD11b
+ cells were the predominant cellular subset
infected (.62% of gfp
+ cells were CD11b
+; Fig. 4C). In contrast,
few if any T cells (identified by CD3; Fig. 4D), B cells (CD19;
Fig. 4E) or NK cells (NK1.1; Fig. 4F) were gfp-positive. These data
identify the CD11b
+ cells, likely splenic macrophages and
potentially neutrophils, as both the principal and selective reservoir
of infection in the spleen.
129Stat1
2/2(N-term) bone marrow dendritic cells
(BMDCs) respond to exogenous Type I IFN in vitro
As shown above, the strain 129Stat1
2/2(N-term) mice exhibited
control of a visceral, but not CNS infection, indicating that either
activation or efficacy of an antiviral pathway might be occurring in
a tissue-specific fashion. To characterize which pathway might be
utilized, we examined the ability of isolated BMDCs from the
deficient mice to control an HSV-1 infection in vitro. Stat1-
deficient BMDCs have been shown to support increased HSV-1
replication relative to wild-type control cells [36]. Furthermore,
AG129 BMDCs are more susceptible than 129Stat1
2/2(N-term)
BMDCs to Dengue virus and Sendai virus, and 129Stat1
2/2
(N-term) BMDCs produce IFN-a and IFN-c in response to
infection [22]. Consistent with a previous report [37], untreated
BMDC’s derived from 129Stat1
2/2(N-term) and AG129 mice
were similarly more productive for HSV-1 infection in a multi-step
growth curve analysis, with titers in the deficient cells nearly 100-
fold greater than titers in cells derived from control mice (Fig. 5A).
Pre-treatment of BMDC’s with exogenous IFN-ß rapidly sup-
pressed viral replication in control cells but had no effect on
replication in AG129 cells (Fig. 5B). Surprisingly, pre-treatment of
129Stat1
2/2(N-term) BMDCs with exogenous IFN-ß reduced
viral replication by approximately 1000-fold, demonstrating a
strong antiviral response in these cells. Similarly, a 100–1,000 fold
reduction of HSV and VSV titers were observed in IFN-ß
pretreated MEFs derived from 129Stat1
2/2(N-term) mice (data
not shown). Pre-treatment of BMDC’s with a Type I IFN receptor
blocking antibody [38] restored viral replication in all three cell
types to that of the untreated 129Stat1
2/2(N-term) and AG129
levels, indicating that the production of IFN in the control cell
cultures was a key factor in controlling HSV replication in these
cells (Fig. 5C). This analysis therefore supports the hypothesis that
the 129Stat1
2/2(N-term) BMDCs respond to Type I IFN pre-
treatment, and suggested that this response was dependent on the
Type I IFN receptor.
Figure 4. Flow cytometry. Identification of the infected cellular subsets within the spleens of AG129 mice. Single-cell suspensions of
spleens from uninfected (A) and AG129 mice infected with KOS64gfp for 96 hours (B) were evaluated for virally-expressed gfp fluorescence by FACS
analysis. To discern which cellular subsets were infected, the gfp
+ cells gated in (B) were analyzed for (C) CD11b, (D) CD3, (E) CD19 and (F) NK1.1
expression. Similar results were observed in multiple mice between 96–100 hours post-infection.
doi:10.1371/journal.pone.0024018.g004
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2/2(N-term) mice
treated with IFNaß receptor (IFNAR) blocking antibody
The above results indicated that 129Stat1
2/2(N-term) BMDCs
respond to exogenous Type I IFN via the IFNAR. This is
consistent with the idea that an IFNAR-dependent response is the
mechanism by which the strain 129Stat1
2/2(N-term) mice clear
the disseminated infection. To test this possibility, control and
129Stat1
2/2(N-term) mice were pre-treated i.p. with an IFNAR
blocking antibody. Mice were then infected via the corneal route
with KOS/Dlux/OriL virus, and monitored by bioluminescent
imaging.
IFNAR antibody-treated control mice showed increased
bioluminescent imaging signals, with bioluminescent signal visible
in the draining lymph nodes between 2 and 4 dpi (data not shown).
Light intensity, however, was still less than that observed in AG129
mice. In contrast, IFNAR antibody-treated 129Stat1
2/2(N-term)
mice showed up to a 1,000 fold increase in photon flux, and closely
resembled the AG129 in terms of their inability to clear the
disseminated visceral infection (Fig. 6). An ROI analysis of the
lymph node and abdominal region of these mice showed levels of
bioluminescent signal comparable to those found in the AG129
mice (Data not shown). Furthermore, the antibody-treated
129Stat1
2/2(N-term) mice died by 5 dpi, identical in time to that
seen in AG129 mice. These data demonstrate that the strain
129Stat1
2/2(N-term) mice had residual signaling via the IFNAR
that was sufficient to alter both viral tropism and survival following
HSV-1 infection.
Bioluminescent imaging of 129Stat1
2/2(N-term) and
129Stat1
2/2(DBD) mice
The results so far in this study indicated a residual ability in the
strain 129Stat1
2/2(N-term) mice to respond to Type I IFN via the
IFNAR. Possible explanations for these observations include
IFNAR-dependent, Stat1-independent redundant pathway for
Type I IFN signaling, or possibly residual Stat1-dependent
activity. To address this, first, the 129Stat1
2/2(N-term) mice
were genotyped to eliminate the possibility that errors in animal
husbandry had caused generation of a heterozygous, or reverted
mouse line (data not shown). Next, we infected a second Stat1
2/2
mouse, 129Stat1
2/2(DBD) (kindly provided by Joan Durbin),
which contains a deletion in the Stat1 DNA binding domain [13].
Similar to the 129Stat1
2/2(N-term) strain this Stat1-deficient
mouse strain also has increased susceptibility to pathogens, and a
defective IFN response [13,22,32,39].
To compare the Stat1
2/2 mouse lines, strain 129Stat1
2/2
(N-term) [12] and 129Stat1
2/2(DBD) [13] mice were infected
with KOS/Dlux/OriL as described above and examined daily by
bioluminescent imaging (Fig. 7). In both mouse strains, an
infection was detected in the draining lymph nodes by 2 dpi and
in the liver and spleen by 3 dpi. As seen previously, by 4 dpi the
generalized infection was controlled in the 129Stat1
2/2(N-term)
mice. In contrast, the 129Stat1
2/2(DBD) mice failed to control
the generalized infection. The pathogenesis of HSV-1 in the
129Stat1
2/2(DBD) mice was similar to that seen in AG129 mice
and to that seen in strain 129Stat1
2/2(N-term) mice treated with
the IFNAR blocking antibody (Fig. 6). ROI analysis of the
bioluminescent signals revealed 10–50 times higher photon flux in
the 129Stat1
2/2(DBD) than the 129Stat1
2/2(N-term) mice
(Fig. 8). Moreover, almost 100-fold more virus (5610
5 pfu/ml of
homogenate compared with 7610
3 pfu/ml) was found in the livers
of 129Stat1
2/2(DBD) mice than in 129Stat1
2/2(N-term) (data
not shown). To eliminate the caveat that the differences in HSV
pathogenesis observed in these two versions of Stat1-deficient
mice were due to differences in background between the two
strains, we performed SNP analysis (http://www.dartmouse.org/).
129Stat1
2/2(DBD) mice showed greater than 97% SNP identity
to 129 Sv/Ev control mice, while the 129Stat1
2/2(N-term) mice
had greater than 99% identity to strain 129 (data not shown). As
an additional control, we also tested the 129Stat1
2/2(DBD)
Figure 5. BMDCs from 129Stat1
2/2(N-term) mice respond to
exogenous Type I IFN. In vitro BMDC cultures were left untreated (A),
pre-treated with 1000 U/mL of IFN-ß (B), or pre- and post-treated with
5 ug/mL of the IFNAR blocking antibody MAR1-5A3 (C). Cells were
infected at an MOI of 0.01 with HSV-1 KOS, and cells and supernatents
were harvested at 6, 24, and 48 hpi for a viral titer analysis. Each point
represents a minimum of 3 measurements from at least 3 independent
experiments.
doi:10.1371/journal.pone.0024018.g005
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bioluminescent imaging and titers relative to 129Stat1
2/2(N-term)
(Figure S2, and data not shown). Together these data eliminate the
possibility that the differences between 129Stat1
2/2(N-term) and
129Stat1
2/2(DBD) are due to subtle background differences in
the two 129 knockout strains [40,41].
Discussion
The role of the interferon response in controlling HSV infection
is well established, but precise roles for certain IFN pathway
components in the determination of tropism have not been
determined. In humans, herpetic encephalitis is a frequently
observed viral CNS infection, while herpetic hepatitis in humans is
relatively rare, accounting for ,2% of viral-induced acute liver
failure. It is most often observed in immunocompromized adults,
in neonates, or during the final trimester of pregnancy. Diagnosis
of HSV in such cases is often missed and effective antiviral
treatment is therefore delayed, thus resulting in a high (,74%)
fatality rate [8]. The utility, therefore, of the AG129 mouse as a
model for herpetic hepatitis is now under further investigation.
Stat1
2/2 mice have been utilized in a large number of studies to
delineate the roles of Stat1 and IFN in controlling infection and
mediating IFN-dependent gene expression. Many studies have
shown increased replication in Stat1
2/2 cells and mice infected
with a variety of pathogens in including Listeria monocytogenes,
vesicular stomatitis virus, herpes simplex virus, Dengue virus,
Sendai virus, mouse norovirus, Sindbis virus, Leishmania major,
yellow fever virus, and mouse cytomegalovirus [12,18,19,20,21,
22,23,26,27,33,42,43]. Overall, these studies showed a similar
pattern of increased replication in target tissues from a variety of
inoculation routes. Several of these studies also reported IFN-
dependent gene expression patterns that were categorized as
Stat1-independent pathways. A recent study indicates that much
of this Stat1-independent activity is dependent on Stat2, since
mice lacking both Stat1 and Stat2 show susceptibility to dengue
Figure 6. 129Stat1
2/2(N-term) mice treated with anti-Type I IFN receptor antibody display visceral infection similar to AG129 mice.
In vivo bioluminescent imaging analysis of untreated 129Stat1
2/2(N-term), IFNaß receptor blocking antibody (MAR1-5A3) treated 129Stat1
2/2
(N-term), and untreated AG129 mice infected with 2610
6 pfu/eye of HSV-1 KOS/Dlux/OriL. Bioluminescent imaging analysis was performed as
described above. A minimum of 5 mice were analyzed and representative images shown. Daily images from the same mice per strain formatted on an
identical scale are shown. For clarity, additional images in the right hand column are shown for 4dpi on a higher photon flux scale to avoid the
saturated image for the AG129 mice.
doi:10.1371/journal.pone.0024018.g006
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from all of these studies whether the IFN-dependent gene
expression wholly arose from Stat1-independent pathways, or
whether it might have resulted, in part, from a small amount of
residual Stat1 activity, especially in the 129Stat1
2/2(N-term)
mice. Despite this possibility, 129Stat1
2/2(N-term) cells lack the
expected responses to IFN treatment with changed expression of
IFN-dependent genes, decreased virus-induced apoptosis, altered
IFN-dependent upregulation of cell surface markers, and increased
susceptibility to pathogens [23,44,45,46]. It is clear therefore, that
the residual activity is only relevant or detectable under certain
specific infection conditions. Moreover, these mice succumb to
HSV encephalitis, a tropism that closely resembles that seen in
some Stat-deficient humans [4]. These mice represent a closer
model of generalized human HSV infection than the 129Stat1
2/2
(DBD) which usually succumb to hepatitis. These mice remain,
therefore, a tractable and useful model of innate immune
insufficiency. Our studies, and studies of several other labs, have
consistently shown greater susceptibility to pathogens in the
AG129 mice as compared to the 129Stat1
2/2(N-term) mice
[18,22,23,30,33]. Indeed, the profound viscerotropism of a variety
of viruses in AG129 mice leads to the general conclusion that Type
I and Type II IFN receptors are essential for protection of visceral
organs from viral infection. It is possible, based on our flow
cytometry data, that this viscerotropism may result from increased
permissivity of monocytes and macrophages which are highly
infected in these mice. These immune cells may serve as a conduit
in which the virus can replicate and spread, and thereby traffic to,
and replicate in the lymph nodes, spleen, liver and other visceral
organs. Previous studies have demonstrated that HSV can
replicate to low levels in leukocytes, [47,48,49,50] and this study
suggests that these cells become more permissive and productive in
the absence of IFN responses. This is also consistent with a
previous study of Dengue virus in AG129 mice in which increased
virus replication was demonstrated in CD11b+ (and other) cells in
the spleen [51].
The Stat1-deficient strains examined in this study have distinct
Stat1-deficient alleles. The 129Stat1
2/2(N-term) mouse lacks the
N-terminal protein-protein interaction domain [12], whereas the
129Stat1
2/2(DBD) [32] and B6Stat1
2/2(DBD) [13] are obviously
identical, lacking the DNA binding domain of Stat1 [13]. Few
direct comparisons of these mice have been reported, but Shresta
et al infected 129Stat1
2/2(N-term) and 129Stat1
2/2(DBD) mice
with Dengue and showed that both strains were resistant to
infection relative to AG129 mice [22]. They also found production
of IFN-a in BMDC cultures following infection of 129Stat1
2/2
(N-term) cells with Dengue and Sindbis virus and from their results
they concluded that Stat1-independent pathways were mediating
IFN expression in these cells. They did not, however, perform the
IFN-a production experiments on the 129Stat1
2/2(DBD) mice.
Experiments in this study indicate that both the 129Stat1
2/2
(N-term) and 129Stat1
2/2(DBD) mice produce IFNa in response
to virus infection (data not shown) suggesting that it is the response
to IFN that differs between these mouse strains, rather than IFN
Figure 7. Bioluminescent imaging comparison of 129Stat1
2/2
(N-term) and 129Stat1
2/2(DBD) mice. In vivo bioluminescent
imaging analysis of control, AG129, 129Stat1
2/2(N-term) and
129Stat1
2/2(DBD) mice was performed on days 2, 3 and 4 postinfec-
tion. Daily images from the same mice per strain formatted on an
identical scale are shown. Images shown are representative of three
independent experiment with at least 2 mice per group per experiment.
doi:10.1371/journal.pone.0024018.g007
Figure 8. Region of interest (ROI) analysis of abdominal
bioluminescence. Analysis of control, 129Stat1
2/2(N-term) and
129Stat1
2/2(DBD) mice (open, gray, and black bars respectively) from
3 independent experiments. Identical boxes surrounding the tissues of
interest (spleen and liver) were drawn with Living Image and IgorPro
software, and bioluminescent signal reported in photons/sec.
doi:10.1371/journal.pone.0024018.g008
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2/2(N-term) mice have an
N-terminal deletion in Stat1 that reduces the molecular weight
from 91 kDa to 72 kDa, diminishes expression of the truncated
protein to 4–7% of the native Stat1 protein, and reduces transcript
levels to 4% of normal levels [12]. It was suggested that an
untranslated exon 3kb upstream of the Stat1 AUG could result in
expression of a mutant form of Stat1 in the gene targeted mice that
initiates at position 135. This protein under most circumstances is
expressed in very limited quantities, and is, for the most part,
functionally inactive. In response to IFN-c treatment, the
truncated Stat1 protein bound DNA at ,2% of wild-type Stat1
levels. Based on experiments with IFN-a and IFN-ctreatment, the
originators of this mouse concluded that these mice produced a
limited amount of a mutated Stat1 protein that was functionally
inactive [12]. The results in this current study suggest, however,
that what might be taken as Stat1-independent, IFN-dependent
signaling may in fact be partly due to residual Stat1 signaling via
the Type I IFN receptor. This hypothesis is best supported by the
observation that antiviral activity is abrogated in the presence of
the Type I IFN receptor-blocking antibody. Additional supporting
data include the observation that the 129Stat1
2/2(DBD) and
B6Stat1
2/2(DBD) are significantly more susceptible to HSV
infection than the 129Stat1
2/2(N-term) mice. It is likely,
therefore, that the Stat1
2/2(DBD) mice represent a more
complete knockout of Stat1 function than the Stat1
2/2(N-term)
mice. An alternate, non-mutually exclusive hypothesis, is based on
the fact that HSV inhibits Stat1 activity, and that it is more
capable of inhibiting the residual antiviral activity of the Stat1
2/2
(DBD) mice than the Stat1
2/2(N-term) mice [52,53,54], Further
characterization of possible residual Stat1 signaling for both Type
I and Type II IFN in the strain 129Stat1
2/2(N-term) mice will be
critical for interpretation of all results based on these mice because,
as shown here, this Stat1 activity is sufficient to significantly alter
HSV-1 pathogenesis. Whether the relative resistance of
129Stat1
2/2(N-term) mice to visceral infection is due to Stat1-
independent pathways, or residual Stat1 activity, is a subject for
further study.
This study also builds on earlier work with mice lacking the
Type I IFN receptor (IFNAR
2/2 or A129 mice) or the Type II
IFN receptor (IFNGR
2/2 or G129 mice) [25]. Previously, A129
mice infected with HSV-1 via the cornea successfully controlled a
transient visceral infection with 100% survival. G129 mice fully
controlled HSV-1 infection, while AG129 showed no control over
the virus [25]. From this it was concluded that the Type II IFN
response alone played a minor role in controlling acute HSV-1
infection, but played a synergistic role with Type I IFN as shown
by the susceptibility of the AG129 mice. A particularly interesting
finding from the current study was that antibody blockade of the
IFNAR in the 129Stat1
2/2(N-term) mouse was sufficient to shift
viral tropism to the liver. This strongly supports the idea of a role
for Type I IFN in controlling HSV-1 infection in the viscera. We
propose that the IFNAR antibody-treated 129Stat1
2/2(N-term)
mice have a completely abrogated Type I IFN function, while
Type II IFN function is only partially reduced due to the
incomplete knockout of Stat1 function in these mice. From these
data, we can assemble a hierarchy of the mouse models in terms of
their ability to control an HSV-1 infection: Control 129 mice .
G129. A129 .129Stat1
2/2(N-term) .129Stat1
2/2(DBD) =
B6Stat1
2/2(DBD) = 129Stat1
2/2(N-term) withIFNARantibody
= AG129.
Finally, our data underscore the utility of bioluminescent
imaging as a rapid screen for changes in viral tropism in mouse
models, and provide us with a tractable model with which to study
the impact of critical components of the innate immune system in
the protection of the brain and liver from herpetic infection. In
addition, our data show that normally benign viruses can be very
dangerous in immune-deficient hosts, and that the ability to clear
such viruses is dependent upon an intact innate response. The
relative contribution of direct viral damage, as opposed to
immune-mediated damage in these model systems is the subject
for future studies, and has important implications for vaccine
design, and prevention of immunopathologic disease.
Materials and Methods
Cells, viruses, and mice
Vero cells were used for amplification and titering of viral stocks
as previously described [55]. The viruses used in this study were in
the KOS background [56]. Construction of the HSV-1 KOS/
Dlux/oriL luciferase-expressing virus was previously described
[57]. KOS64gfp (VanHeyningen and Leib, unpublished data)
contains a cassette comprising the HCMV promoter driving gfp
inserted into the Bgl II site at the map position previously described
for KOS6B [58]. Mock-treated animals were inoculated with
uninfected Vero cell lysates prepared in a parallel manner as
infected Vero lysates. Mouse strains used included the control
129S6 as wild type mice (Taconic Farms, Germantown, NY), 129
S6 Stat1 knock-out mice lacking the N-terminal domain
(129Stat1
2/2(N-term)) [12], 129 IFNaßcR
2/2 mice (AG129)
[15]. These mice were compared to Stat1 deficient mice lacking
the DNA binding domain in both 129, referred to as 129Stat1
2/2
(DBD) (kindly provided by Joan Durbin) [32], and C57BL/6
(B6Stat1
2/2(DBD)) backgrounds [13]. 129Stat1
2/2(N-term) mice
were genotyped to ensure proper husbandry. The genetic
backgrounds of the 129Stat1
2/2(DBD) mice were additionally
assessed at the DartMouse
TM Speed Congenic Core Facility at
Dartmouth Medical School. DartMouse uses the Illumina, Inc.
(San Diego, CA) GoldenGate Genotyping Assay to interrogate
1449 SNPs spread throughout the genome. The raw SNP data
were analyzed using DartMouse’s proprietary SNaP-Map
TM and
Map-Synth
TM software, allowing the determination for each
mouse of the genetic background at each SNP location. Mice were
housed in the Washington University School of Medicine and
Dartmouth Medical School barrier facilities, and infected in the
respective biohazard facilities. At both facilities, sentinel mice were
screened every 3 months and determined to be negative for
adventitious mouse pathogens, in particular mouse norovirus.
Mice were infected between 6–8 weeks of age. Mice were housed,
treated, and euthanized when necessary in accordance with all
Federal and University policies.
Animal infection procedures
For corneal infection, equivalent numbers of 6–8 week old male
and female mice were anesthetized intraperitoneally with
ketamine (87 mg/kg body weight) and xylazine (13 mg/kg).
Corneas were bilaterally scarified with a 25G syringe needle and
virus was inoculated by adding 2610
6 pfu in a 5 ml volume [55].
Mice were sacrificed at the specified time post-infection for
determination of tissue viral titers or sample harvest. Eye swab
material was collected for a standard plaque assay as previously
described [55]. Liver, spleen, cervical lymph nodes, brain, brain
stem, and serum were collected. All tissues were harvested into an
appropriate volume of media and stored at 280uC. Tissue homo-
genization was accomplished with 1 mm or 3 mm glass beads.
Whole blood was collected from infected mice at the indicated
time post-infection. Serum was isolated using BD Microtainer
serum separator tubes (Becton Dickinson, Franklin Lakes, NJ) and
viral load in serum was determined by plaque analysis on Vero
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from three or four independent groups of mice. Tissue titers are
reported as pfu per tissue, except for the cervical lymph nodes, in
which two tissues were combined into one sample. Selected
animals were pre-treated with 2.0 mg i.p. of anti-mouse IFN a/ß
receptor (Clone MAR1-5A3; IFNAR1 subunit) antibody (Leinco
Technologies Inc, St Louis, MO) one day prior to corneal
infection, and re-treated again with 0.2 mg antibody at day 3 post-
infection [38].
Bioluminescence imaging
Mice infected via the corneal route with KOS/Dlux/OriL were
imaged with a cooled charge-coupled device (CCD) camera-based
bioluminescence (IVIS 100, Caliper LifeSciences, Hopkinton,
MA) as previously described [35]. For bioluminescence imaging of
living animals, infected mice were injected intraperitoneally with
150 mg/g D-luciferin (Biosynth, Naperville, IL) in PBS, anesthe-
tized with 2.5% isofluorane, and imaged (exposure time 1–60
seconds, binning 8, field of view 15 or 19.6, f/stop 1 or 2, open
filter, anterior side). Signal was displayed as photons/sec/cm
2/sr.
For analysis, regions of interest (ROI) were defined manually
around the lymph nodes, liver and spleen, and perinasal cavity and
photon flux (photons/sec) calculated using Living Image and
IgorPro Software (Version 2.50). Ex vivo images were obtained
immediately after live imaging.
Flow Cytometry
Mice were infected via the cornea with 2610
6 pfu per eye of
KOS64gfp. Spleens were removed 100 hours postinfection and
single-cell suspensions were generated by passage through a
70 mM cell strainer (BD Biosciences, San Jose, CA). The cellular
fraction was treated with ACK lysis buffer (0.15 M NH4Cl,
1.0 mM KHCO3, 0.1 mM EDTA) to remove red blood cells, and
the remaining cells were resuspended in 0.5% BSA in PBS or
media for analysis. Cells were pre-incubated with Fc-blocking
antibody (clone 2.4G2) prior to antibody staining. Anti-mouse
antibodies against CD3 (145-2C11), CD11b (M1/70), NK1.1
(PK136), and CD19 (1D3) were purchased from eBioscience (San
Diego, CA). Flow cytometry was done on the Accuri C6 and
analyzed using CFlow and FlowJo 8.8.2 software.
BMDCs
Bone marrow dendritic cells were harvested as previously
described [37]. Briefly, bone marrow was flushed from both
femurs of adult mice and cultured in RPMI supplemented with
10% FBS, Glutamax, sodium pyruvate, 250 U of penicillin/mL,
250 U of streptomycin/mL, and 2% GM-CSF. At 6 days post-
harvest, BMDC’s were collected, counted, and infected at an
MOI=0.01. BMDC’s were pretreated 18 hrs prior to infection
with recombinant mouse IFNß (PBL Interferon Source) at
1000 U/mL culture media or with anti-mouse IFN a/ß receptor
(Clone MAR1-5A3; IFNAR1 subunit) antibody (Leinco Technol-
ogies Inc) at 5 mg/mL culture media.
Supporting Information
Figure S1 Ex vivo bioluminescence of infected tissues
defines source of in vivo bioluminescence. Immediately
following in vivo bioluminescent imaging at 3 or 6 dpi, 129Stat1
2/2
(N-term) and AG129 infected with 2610
6 pfu/eye of HSV-1 KOS/
Dlux/OriL were sacrificed and dissected to examine brain, brain
stem, trigeminal ganglia, liver, and spleen using ex vivo biolumines-
cent imaging.
(TIF)
Figure S2 Region of interest (ROI) analysis of lymph
node and abdominal bioluminescence. Images collected
from control, 129Stat1
2/2(N-term), AG129, 129Stat1
2/2(N-term)
treated with IFNaßR-blocking antibody, and B6Stat1
2/2(DBD)
micewere analyzed for bioluminescent signal by quantitation in two
ROIs. Identical boxes surrounding the tissues of interest (cervical
lymph nodes, spleen and liver) were drawn with Living Image and
IgorPro software, and bioluminescent signal reported in photons/
sec.
(TIF)
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